RESUMEN
Introduction: in Senegal, cervical cancer is the leading cause of cancers among women. This study estimated the costs associated with cervical cancer screening and treatment for precancerous lesions from the health system perspective. Methods: we estimated costs for screening, diagnostics, and treatment. We conducted a cross-sectional study in seven regions with primary data collected from 50 health facilities. Data collection included structured questionnaires, with secondary data from the Ministry of Health and other sources. A mixed-methods approach combined ingredients-based costing and financial expenditures to estimate direct medical and non-medical costs. All costs are reported in 2019 USD. Results: average costs were $3.71 for visual inspection with acetic acid, $16.49 for Pap smear, and $46.65 for human papillomavirus deoxyribonucleic acid (HPV DNA) testing. Screening cost drivers were clinical exam supplies and clinical equipment for visual inspection with acetic acid, offsite processing of specimens for Pap smear, and lab equipment costs for HPV DNA procedure. The average cost of diagnosis via colposcopy alone was $25.73, and colposcopy with biopsy/endocervical curettage was $74.96. The average cost of treatment followed by one visit for pre-cancerous lesions was $195.24 for loop electrosurgical excision, $47.35 for cryotherapy, and $32.35 for thermal ablation. Clinical equipment and lab costs were the largest contributors to colposcopy and endocervical curettage/biopsy expenses. Clinical equipment made up the largest portion of cryotherapy, loop electrosurgical excision, and thermoablation costs. Conclusion: this study is the first to estimate the costs of HPV screening and treatment in Senegal, which can be used to inform decision-making on cervical cancer investments.
Asunto(s)
Colposcopía , Detección Precoz del Cáncer , Tamizaje Masivo , Prueba de Papanicolaou , Neoplasias del Cuello Uterino , Frotis Vaginal , Humanos , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias del Cuello Uterino/economía , Neoplasias del Cuello Uterino/terapia , Femenino , Senegal , Estudios Transversales , Detección Precoz del Cáncer/economía , Prueba de Papanicolaou/economía , Frotis Vaginal/economía , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Colposcopía/economía , Costos de la Atención en Salud/estadística & datos numéricos , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/economía , Encuestas y Cuestionarios , Pruebas de ADN del Papillomavirus Humano/economía , Ácido Acético , Lesiones Precancerosas/diagnóstico , Lesiones Precancerosas/economía , Lesiones Precancerosas/terapia , Biopsia/economíaAsunto(s)
Vacunas contra Papillomavirus , Humanos , Vacunas contra Papillomavirus/economía , Femenino , Adolescente , Alemania , Programas Nacionales de Salud/economía , Programas Nacionales de Salud/legislación & jurisprudencia , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/economía , Mecanismo de Reembolso/economía , Mecanismo de Reembolso/legislación & jurisprudencia , Neoplasias del Cuello Uterino/prevención & control , Neoplasias del Cuello Uterino/economía , Adulto JovenRESUMEN
BACKGROUND: Human papillomavirus (HPV) causes several cancers such as cervical cancer and some head and neck (oral cavity, pharynx, and larynx), vulval, vaginal, anal, and penile cancers. As HPV vaccination is available, there is potential to prevent these cancers attributed to HPV and consequently the burden associated with them. The aim of this analysis was to estimate the number of HPV-related cancer deaths and the productivity costs due to years of life lost (YLL) in the United Kingdom (UK). METHOD: A model was developed utilizing UK 2019 mortality data sourced from country-specific databases for England, Scotland, Wales, and Northern Ireland for the following HPV-related cancers: head and neck (ICD-10 C00-14 and C32), cervix uteri (C53), vaginal (C51), vulval (C52), anal (C21), and penile (C60). The proportion of deaths and years of life lost (YLL) due to HPV were estimated using HPV attributable fractions for each anatomic location from the published literature. Labor force participation, retirement ages, and mean annual earnings, discounted at 3.5% annually, were applied to YLL to calculate the present value of future lost productivity (PVFLP). RESULTS: A total of 1817 deaths due to HPV-related cancers were reported in the UK in 2019 resulting in 31,804 YLL. Restricting to only YLL that occurred prior to retirement age yielded a total YPLL of 11,765 and a total PVFLP of £187,764,978. CONCLUSIONS: There is a high disease burden in the UK for HPV-related cancers, with a large economic impact on the wider economy due to productivity losses. Implementing and reinforcing public health measures to maintain high HPV vaccination coverage in both males and females may further facilitate reduction of this burden.
Asunto(s)
Infecciones por Papillomavirus , Humanos , Reino Unido/epidemiología , Femenino , Masculino , Infecciones por Papillomavirus/complicaciones , Infecciones por Papillomavirus/economía , Infecciones por Papillomavirus/mortalidad , Persona de Mediana Edad , Neoplasias/mortalidad , Neoplasias/economía , Adulto , Anciano , Eficiencia , Costo de Enfermedad , Modelos Econométricos , Vacunas contra Papillomavirus/economía , Vacunas contra Papillomavirus/administración & dosificación , Neoplasias del Cuello Uterino/mortalidad , Neoplasias del Cuello Uterino/economía , Neoplasias del Cuello Uterino/virología , Virus del Papiloma HumanoRESUMEN
BACKGROUND: Infections are responsible for approximately 13% of cancer cases worldwide and many of these infections can be prevented by vaccination. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the most common infections that cause cancer deaths globally, despite effective prophylactic vaccines being available. This analysis aims to estimate the global burden and economic impact of vaccine-preventable cancer mortality across World Health Organization (WHO) regions. METHODS: The number of deaths and years of life lost (YLL) due to five different vaccine-preventable cancer forms (oral cavity, liver, laryngeal, cervical, and oropharyngeal cancer) in each of the WHO regions (African, Eastern Mediterranean, European, the Americas, South-East Asia Pacific, and Western Pacific) were obtained from the Institute for Health Metrics Evaluation global burden of disease dataset. Vaccine-preventable mortality was estimated considering the fraction attributable to infection, to estimate the number of deaths and YLL potentially preventable through vaccination. Data from the World Bank on GDP per capita were used to estimate the value of YLL (VYLL). The robustness of these results was explored with sensitivity analysis. Given that several Epstein-Barr virus (EBV) vaccines are in development, but not yet available, the impact of a potential vaccine for EBV was evaluated in a scenario analysis. RESULTS: In 2019, there were 465,740 potentially vaccine-preventable cancer deaths and 14,171,397 YLL across all WHO regions. The estimated economic impact due to this mortality was $106.3 billion globally. The sensitivity analysis calculated a range of 403,025-582,773 deaths and a range in productivity cost of $78.8-129.0 billion. In the scenario analysis EBV-related cancer mortality increased the global burden by 159,723 deaths and $32.4 billion. CONCLUSION: Overall, the findings from this analysis illustrate the high economic impact of premature cancer mortality that could be potentially preventable by vaccination which may assist decision-makers in allocating limited resources among competing priorities. Improved implementation and increased vaccination coverage of HPV and HBV should be prioritized to decrease this burden.
Asunto(s)
Salud Global , Neoplasias , Humanos , Neoplasias/mortalidad , Neoplasias/economía , Femenino , Masculino , Carga Global de Enfermedades , Costo de Enfermedad , Enfermedades Prevenibles por Vacunación/prevención & control , Enfermedades Prevenibles por Vacunación/economía , Persona de Mediana Edad , Adulto , Modelos Econométricos , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/economía , Años de Vida Ajustados por Calidad de VidaRESUMEN
While the incidence of cervical cancer has dropped in high-income countries due to organized cytology-based screening programs, it remains the leading cause of cancer death among women in Eastern Africa. Therefore, the World Health Organization (WHO) now urges providers to transition from widely prevalent but low-performance visual inspection with acetic acid (VIA) screening to primary human papillomavirus (HPV) DNA testing. Due to high HPV prevalence, effective triage tests are needed to identify those lesions likely to progress and so avoid over-treatment. To identify the optimal cost-effective strategy, we compared the VIA screen-and-treat approach to primary HPV DNA testing with p16/Ki67 dual-stain cytology or VIA as triage. We used a Markov model to calculate the budget impact of each strategy with incremental quality-adjusted life years and incremental cost-effectiveness ratios (ICER) as the main outcome. Deterministic cost-effectiveness analyses show that the screen-and-treat approach is highly cost-effective (ICER 2469 Int$), while screen, triage, and treat with dual staining is the most effective with favorable ICER than triage with VIA (ICER 9943 Int$ compared with 13,177 Int$). One-way sensitivity analyses show that the results are most sensitive to discounting, VIA performance, and test prices. In the probabilistic sensitivity analyses, the triage option using dual stain is the optimal choice above a willingness to pay threshold of 7115 Int$ being cost-effective as per WHO standards. The result of our analysis favors the use of dual staining over VIA as triage in HPV-positive women and portends future opportunities and necessary research to improve the coverage and acceptability of cervical cancer screening programs.
Asunto(s)
Análisis de Costo-Efectividad , Detección Precoz del Cáncer , Infecciones por Papillomavirus , Población Rural , Neoplasias del Cuello Uterino , Adulto , Femenino , Humanos , Persona de Mediana Edad , Ácido Acético , Detección Precoz del Cáncer/economía , Detección Precoz del Cáncer/métodos , Kenia/epidemiología , Cadenas de Markov , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/virología , Infecciones por Papillomavirus/economía , Infecciones por Papillomavirus/epidemiología , Años de Vida Ajustados por Calidad de Vida , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias del Cuello Uterino/virología , Neoplasias del Cuello Uterino/economía , Neoplasias del Cuello Uterino/epidemiologíaRESUMEN
BACKGROUND: Human papilloma virus (HPV) is a common cause of several types of cancer, including head and neck (oral cavity, pharynx, oropharynx, hypopharynx, nasopharynx, and larynx), cervical, vulval, vaginal, anal, and penile cancers. As HPV vaccines are available, there is potential to prevent HPV-related disease burden and related costs. METHOD: A model was developed for nine Central Eastern European (CEE) countries (Bulgaria, Croatia, Czechia, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia). This model considered cancer patients who died from 11 HPV-related cancers (oropharynx, oral cavity, nasopharynx, hypopharynx, pharynx, anal, larynx, vulval, vaginal, cervical, and penile) in 2019. Due to data limitations, Bulgaria only included four cancer types. The model estimated the number of HPV-related deaths and years of life lost (YLL) based on published HPV-attributable fractions. YLL was adjusted with labor force participation, retirement age and then multiplied by mean annual earnings, discounted at a 3% annual rate to calculate the present value of future lost productivity (PVFLP). RESULTS: In 2019, there were 6,832 deaths attributable to HPV cancers resulting in 107,846 YLL in the nine CEE countries. PVFLP related to HPV cancers was estimated to be 46 M in Romania, 37 M in Poland, 19 M in Hungary, 15 M in Czechia, 12 M in Croatia, 10 M in Serbia, 9 M in Slovakia, 7 M in Bulgaria and 4 M in Slovenia. CONCLUSIONS: There is a high disease burden of HPV-related cancer-related deaths in the CEE region, with a large economic impact to society due to substantial productivity losses. It is critical to implement and reinforce public health measures with the aim to reduce the incidence of HPV-related diseases, and the subsequent premature cancer deaths. Improving HPV screening and increasing vaccination programs, in both male and female populations, could help reduce this burden.
Asunto(s)
Costo de Enfermedad , Infecciones por Papillomavirus , Humanos , Infecciones por Papillomavirus/complicaciones , Infecciones por Papillomavirus/economía , Femenino , Masculino , Europa Oriental/epidemiología , Neoplasias/economía , Neoplasias/mortalidad , Persona de Mediana Edad , Eficiencia , Esperanza de Vida , Adulto , Europa (Continente)/epidemiología , Anciano , Modelos Econométricos , Virus del Papiloma HumanoRESUMEN
INTRODUCTION: The UK implemented a single-dose HPV vaccination policy in September 2023, aiming for sustained protection, better vaccine coverage, and reduced healthcare costs. This research assesses the cost-effectiveness of both one-dose and two-dose schedules from a healthcare perspective. METHODS: Using an age-structured dynamic model, the study analyzed long-term health and economic outcomes of these two different vaccination approaches. It focused on the effects of vaccinating 12- to 13-year-olds with the 9-valent HPV vaccine in either single-dose or two-dose regimens from 2023 to 2093. The analysis, conducted in 2023-2024, explored different immunity durations (10, 30 years, or lifetime) and efficacy levels for the single-dose strategy. RESULTS: The study indicated that in the UK, vaccinating 12- to 13-year-olds with a two-dose regimen is not considered cost-effective compared to the single-dose option, assumed to be 90% as effective for 10 years. The incremental cost-effectiveness ratios for two doses ranged from £230,903 to £1,082,916 per quality-adjusted life year (QALY), significantly exceeding the UK's £20,000/QALY willingness-to-pay threshold. Over 70 years, a switch from a two-dose to a single-dose vaccination schedule could potentially lead to savings of over £1,073 million in the healthcare system. Furthermore, the single-dose regimen was cost-effective compared to no vaccination, with an incremental cost-effectiveness ratio below £2,040/QALY. CONCLUSIONS: The study affirms the cost-effectiveness of the UK's single-dose HPV vaccine, in sync with its September 2023 policy shift. The shift not only provides financial benefits but also simplifies vaccine administration, strategically reducing HPV's epidemiological and economic impacts.
Asunto(s)
Análisis Costo-Beneficio , Infecciones por Papillomavirus , Vacunas contra Papillomavirus , Humanos , Vacunas contra Papillomavirus/administración & dosificación , Vacunas contra Papillomavirus/economía , Reino Unido , Adolescente , Femenino , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/economía , Niño , Años de Vida Ajustados por Calidad de Vida , Vacunación/economía , Esquemas de Inmunización , Adulto Joven , Adulto , Virus del Papiloma HumanoRESUMEN
Vaccines to protect against human papillomavirus (HPV) infection are recommended for all adolescents by the World Health Organization (WHO) and are primarily delivered in school-based settings. This systematic review aims to summarize the available evidence on the cost of HPV vaccine delivery in low- and middle-income countries (LMICs). This updated evidence is eminent given recent global efforts to revitalize HPV vaccine delivery following the COVID-19 pandemic and can be used to inform planning for program sustainability. We carried out a systematic review of published literature reporting the costs of HPV vaccine delivery in LMICs published between 2005 and 2023. Eligibility criteria were developed using the Population, Intervention, Comparator, Outcome (PICO) framework, and studies that reported primary costing data and unit costs of HPV vaccine delivery were included. From the included studies, we extracted data such as phase of HPV vaccine implementation when costing was done, delivery strategy, and unit costs. Unit costs were converted into 2022 US$ for comparability. All included studies underwent critical appraisal using an adapted framework including Consolidated Health Economics Evaluation Reporting Standards criteria, the WHO-led consensus statement on vaccine delivery costing, and other frameworks. Our research identified 226 records, of which 15 met our inclusion criteria. Most studies (64 %) were carried out in African countries and during HPV vaccine pilots or demonstrations (60 %). Vaccine delivery cost ranged from $0.31 to $24.07 per dose for financial costs and $1.48 to $48.70 per dose for economic costs. The critical appraisal showed that most studies did not describe the uncertainty of reported delivery cost. Our systematic review evidence suggests that HPV vaccine delivery costs vary widely depending on country and stage of implementation when costing was done. Areas for further research include costing when programs are beyond the introduction phase and in LMICs outside of Africa.
Asunto(s)
Países en Desarrollo , Infecciones por Papillomavirus , Vacunas contra Papillomavirus , Humanos , Vacunas contra Papillomavirus/economía , Vacunas contra Papillomavirus/administración & dosificación , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/economía , COVID-19/prevención & control , COVID-19/economía , Femenino , Vacunación/economía , Adolescente , Programas de Inmunización/economía , Análisis Costo-BeneficioRESUMEN
Abstract Objective Themain objective of the present study was to estimate the annual treatment costs of invasive cervical cancer (ICC) per patient at an oncology center in Brazil from a societal perspective by considering direct medical, direct nonmedical, and indirect costs. Methods A cost analysis descriptive study, in which direct medical, direct nonmedical, and indirect costs were collected using a microcosting approach, was conducted between May 2014 and July 2016 from a societal perspective. The study population consisted of women diagnosed with ICC admitted to a tertiary hospital in Recife, state of Pernambuco, Brazil. The annual cost per patient was estimated in terms of the value of American Dollars (US$) in 2016. Results From a societal perspective, the annual ICC treatment cost per patient was US $ 2,219.73. Direct medical costs were responsible for 81.2% of the total value, of which radiotherapy and outpatient chemotherapy had the largest share. Under the base-case assumption, the estimated cost to the national budget of a year of ICC treatment in the Brazilian population was US$ 25,954,195.04. Conclusion We found a high economic impact of health care systems treating ICC in a poor region of Brazil. These estimates could be applicable to further evaluations of the cost-effectiveness of preventing and treating ICC.
Resumo Objetivo O objetivo principal do presente estudo foi estimar os custos anuais por paciente do tratamento do câncer do colo do útero (CCU) invasivo em um centro de oncologia no Brasil, sob a perspectiva da sociedade, considerando os custos diretos médicos, diretos não médicos e indiretos. Métodos Foi realizado um estudo descritivo de análise de custos, no qual os custos médicos diretos, não médicos diretos e indiretos foram coletados por meio de uma abordagem de microcustos, realizado entre maio de 2014 e julho de 2016 sob a perspectiva da sociedade. A população do estudo foi composta por mulheres diagnosticadas com CCU invasivo internadas em um hospital terciário em Recife, PE, Brasil. O custo anual por paciente foi estimado emtermos de dólares americanos (US$) para o ano de 2016. Resultados O custo anual do tratamento do CCU invasivo sob a perspectiva da sociedade foi de US$ 2.219,73 por paciente. Os custos médicos diretos foram responsáveis por 81,2% do valor total, dos quais a radioterapia e a quimioterapia ambulatorial tiveram a maior participação. Sob o pressuposto do caso base, o custo estimado para o orçamento nacional de um ano de tratamento do CCU invasivo na população brasileira foi de US$ 25.954.195,04. Conclusão Foi encontrado um alto impacto econômico dos sistemas de saúde para o tratamento do CCU invasivo em uma região pobre do Brasil. Essas estimativas poderão ser aplicáveis emavaliações adicionais do custo-efetividade da prevenção e tratamento do CCU.
Asunto(s)
Humanos , Femenino , Adulto , Anciano , Anciano de 80 o más Años , Adulto Joven , Procedimientos Quirúrgicos Ginecológicos/economía , Neoplasias del Cuello Uterino/economía , Tamizaje Masivo/economía , Costos de la Atención en Salud/estadística & datos numéricos , Infecciones por Papillomavirus/economía , Detección Precoz del Cáncer/economía , Frotis Vaginal , Brasil/epidemiología , Neoplasias del Cuello Uterino/prevención & control , Neoplasias del Cuello Uterino/terapia , Neoplasias del Cuello Uterino/epidemiología , Costos y Análisis de Costo , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/terapia , Infecciones por Papillomavirus/epidemiología , Vacunas contra Papillomavirus/economía , Investigación sobre Servicios de Salud , Hospitalización/estadística & datos numéricos , Persona de Mediana EdadRESUMEN
Objetivo. Evaluar la costo-efectividad (CE) de la vacuna tetravalente contra el virus de papiloma humano (VPH) en Argentina, desde la perspectiva del sistema de salud. Material y métodos. Se utilizó un modelo dinámico de transmisión para estimar el impacto en la incidencia de cáncer de cuello uterino (Cacu), verrugas y otras lesiones, en los años de vida ajustados por calidad (AVAC) y en costos sanitarios. Resultados. La vacuna podría reducir en 60% el riesgo de muerte por Cacu y en 67% el de padecer verrugas genitales. Comparada con no vacunar, la estrategia de vacunación mostró un beneficio incremental promedio de 0.00234 AVAC por persona a un costo incremental de 2.36 dólares, con una CE de 1007.55 dólares por AVAC ganado. Los resultados demostraron ser robustos en el análisis de sensibilidad. Conclusiones. La inmunización resultaría costo-efectiva, con una CE inferior a un producto interno bruto per cápita (15 009 dólares) por AVAC ganado.
Objective. To assess the cost-effectiveness of the quadrivalent vaccine against human papillomavirus (HPV) in Argentina from the health system perspective. Materials and methods. A dynamic transmission model was used to estimate the impact of the vaccine on the incidence of cervical cancer, warts, and other HPV related diseases; in quality adjusted life years (QALYs); and in healthcare costs. Results. Vaccination could reduce the risk of cervical cancer by 60% and by 67% the risk of genital warts. Compared to a non-vaccine scenario, the immunization strategy showed an incremental benefit of 0.00234 QALY per person at an incremental cost of US$2.36, resulting in an incremental cost-effectiveness ratio of US$1007.55 per QALY gained. Sensitivity analysis proved the robustness of these results. Conclusions. Immunization with the quadrivalent vaccine was a cost-effective intervention in Argentina, and it was far below the threshold of one gross domestic product per capita (US$15 009) per QALY gained.
Asunto(s)
Humanos , Femenino , Niño , Condiloma Acuminado/prevención & control , Neoplasias del Cuello Uterino/prevención & control , Vacunación/economía , Infecciones por Papillomavirus/prevención & control , Vacuna Tetravalente Recombinante contra el Virus del Papiloma Humano Tipos 6, 11 , 16, 18/economía , Neoplasias de los Genitales Femeninos/prevención & control , Argentina , Condiloma Acuminado/virología , Neoplasias del Cuello Uterino/virología , Análisis Costo-Beneficio , Años de Vida Ajustados por Calidad de Vida , Infecciones por Papillomavirus/economía , Infecciones por Papillomavirus/transmisión , Producto Interno Bruto , Neoplasias de los Genitales Femeninos/virología , Modelos TeóricosRESUMEN
Background: Human papillomavirus (HPV) infection is a risk factor for cervical cancer and can be prevented with the HPV vaccine. Aim: To explore the willingness of parents to pay for HPV vaccine for their offspring. Material and Methods: A survey about the willingness to pay for HPV vaccine was answered by 386 individuals of the highest socioeconomic level who had a daughter aged between 12 and 18 years. The survey included information about the risks of HPV infection. Results: Parents would pay a mean of US$ 758 for the vaccine. Twenty five percent of parents were not willing to pay for it. If the cost of the vaccine would be reduced by 50%, only 4% of parents would not pay for it. The willingness to pay is associated with the price of the vaccine, the income level of respondents and the size of the family. Conclusions: Most respondents would pay for HPV vaccine for their daughters, despite the relatively high cost.
Asunto(s)
Adolescente , Niño , Femenino , Humanos , Financiación Personal/estadística & datos numéricos , Infecciones por Papillomavirus/economía , Vacunas contra Papillomavirus/economía , Chile , Conducta de Elección , Composición Familiar , Financiación Personal/economía , Modelos Económicos , Infecciones por Papillomavirus/prevención & control , Encuestas y Cuestionarios , Factores Socioeconómicos , Población UrbanaRESUMEN
Objetivos. Estimar el costo-utilidad de la vacuna contra el Virus de Papiloma Humano (VPH) en las mujeres peruanas luego de la aplicación de la vacuna cuando tenían 10 años de edad. Materiales y métodos. Se realizó un análisis de costo-utilidad empleando el modelo oculto de Markov en una cohorte hipotética de mujeres peruanas, basado en la información de parámetros epidemiológicos, costos asociados al Cáncer de cuello uterino (CCU) y la eficacia y los costos de la vacunación contra el VPH. Los costos de la vacunación se estimaron desde la perspectiva del Ministerio de Salud de Perú y se compararon con los años de vida ajustados por calidad (AVAC) utilizando una tasa de descuento del 5 por ciento. Resultados. El costo anual de la vacunación fue de USD 16 861 490, para el tamizaje con Papanicolau fue de USD 3 060 793 y los costos asociados al CCU fueron de USD 15 580 000. La razón de costo-utilidad incremental (RCUI) fue de 6775 USD/AVAC. Conclusiones. La vacunación contra el VPH puede resultar costo-útil comparada con el no vacunar.
Objetives. To estimate the cost-utility of the vaccine against the Human Papiloma Virus (HPV) in peruvian women after the application of the vaccine at 10 years of age. Materials and methods. A cost-utility analysis was performed using the Markov´s hidden model in a hypothetical cohort of peruvian women, based on the information on epidemiological parameters, costs associated to uterine cervical cancer (UCC) and the efficacy and costs of the vaccine against the HPV. The vaccination costs were estimated from the Peruvian Ministry of Health perspective and were compared against the quality-adjusted life years (QALYs), using a discount rate of 5 percent. Results. The annual cost of the vaccination was USD 16861,490, for the Papanicoau screening it was USD 3060,793 and the costs associated to the UCC were USD 15580,000. The incremental cost utility ratio (ICUR) was 6,775 USD/QALY. Conclusions. Vaccination against HPV can be cost-utility compared to not vaccinating.